Opportunity Information: Apply for RFA AI 23 021
The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) funding opportunity (RFA-AI-23-021) is an NIH cooperative agreement designed to stand up a central hub that keeps the broader ReVAMPP effort organized, connected, and operating as a true network. The CDSC is meant to work hand-in-hand with multiple ReVAMPP Centers; together, the CDSC plus those Centers make up the ReVAMPP Network. The overall aim is pandemic preparedness, specifically by accelerating and coordinating research that supports vaccines and monoclonal antibodies across targeted virus families, while keeping data, tools, and approaches aligned across participating groups. This FOA is explicitly listed as UG3/UH3 and "Clinical Trial Not Allowed," which signals a phased cooperative structure focused on planning/early activities and then implementation, but not on running clinical trials under this particular award.
At its core, the CDSC is expected to function as the operational backbone of the ReVAMPP Network. That includes supporting, coordinating, and managing both ongoing and planned network activities so that the Centers are not working in silos. A major deliverable is a collaborative platform for data sharing that can be used to harmonize and standardize key inputs across the network, such as reagents, assays, and animal models. The CDSC is also expected to make it easier for Centers to exchange knowledge related to structure/function-based vaccine solutions and antigen or immunogen design, which are central themes in modern vaccine R&D. Another important responsibility is helping the network assess and compare the utility of different vaccine technology platforms for the virus families being studied by the ReVAMPP Centers, so that decisions and research directions can be informed by shared evidence rather than isolated experiences.
Beyond technical coordination, the CDSC has a strong communications and project-management mandate. It must facilitate effective communication across all ReVAMPP Centers by scheduling and managing meetings, building routines for regular coordination, and ensuring that information is captured and distributed efficiently. The center is also expected to track overall network progress and outputs, which typically implies establishing shared milestones, reporting structures, and mechanisms to monitor deliverables across sites. In addition, the CDSC should actively create opportunities for collaboration, for example by forming working groups around shared scientific or operational challenges, and by providing administrative and informatics support that helps those working groups produce usable, network-wide outputs.
The FOA also makes clear that the CDSC is not only inward-facing. Under the direction of NIAID, the CDSC is expected to collate information and facilitate exchange with other NIAID/NIH programs, U.S. Government partners, and other key stakeholders. The opportunity specifically names external stakeholders such as the World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF), and the Coalition for Epidemic Preparedness Innovations (CEPI), among others as appropriate. In practical terms, this positions the CDSC as a liaison that can translate and share non-confidential network activities, align where possible with related initiatives, and reduce duplication by keeping the ReVAMPP Network connected to the wider pandemic preparedness ecosystem.
From an administrative standpoint, this is a discretionary funding opportunity using a cooperative agreement mechanism, meaning NIH (here, NIAID) is expected to have substantial programmatic involvement rather than acting only as a passive funder. The activity category is Health, and the CFDA number listed is 93.855. The award ceiling shown is $1,500,000. The FOA anticipated awards field is not specified in the provided text. The original closing date was June 8, 2023, and the opportunity was created March 16, 2023.
Eligibility is broad across typical U.S. applicant categories, including state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, U.S. territories or possessions, and eligible federal agencies. At the same time, it draws clear boundaries around foreign involvement: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply, but foreign components are allowed as defined by the NIH Grants Policy Statement. This distinction generally means a U.S. applicant can include certain foreign collaborations or performance sites if justified and compliant, but the applying organization itself must be domestic and cannot be a non-U.S. institution.
Overall, the opportunity is best understood as funding the shared infrastructure and coordination function for a multi-center pandemic preparedness network: building the systems for data and resource sharing, aligning methods and models, organizing working relationships, tracking network productivity, and serving as an NIAID-directed connector to other major public and global health stakeholders. The scientific advances produced by the ReVAMPP Centers are intended to move faster and be more comparable and reusable precisely because the CDSC keeps the network synchronized on platforms, standards, and communication.Apply for RFA AI 23 021
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2023-03-16.
- Applicants must submit their applications by 2023-06-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the ReVAMPP CDSC funding opportunity (RFA-AI-23-021)?
RFA-AI-23-021 funds a Coordination and Data Sharing Center (CDSC) for the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose is to stand up a central hub that keeps the broader ReVAMPP effort organized, connected, and operating as a true network rather than as independent, siloed projects.
What is the CDSC expected to do within the ReVAMPP Network?
The CDSC is expected to function as the operational backbone of the ReVAMPP Network. It supports, coordinates, and manages network activities so participating ReVAMPP Centers remain aligned on shared goals, methods, and outputs. Key expectations include facilitating collaboration, organizing communications, tracking progress, and enabling consistent data and resource sharing across the network.
How does the CDSC relate to the ReVAMPP Centers?
The CDSC works hand-in-hand with multiple ReVAMPP Centers. Together, the CDSC plus those Centers make up the ReVAMPP Network. The CDSC role is to connect and coordinate the Centers so their work is comparable, reusable, and accelerated through common standards and shared infrastructure.
What is the overall aim of the ReVAMPP Network?
The overall aim is pandemic preparedness. The network is intended to accelerate and coordinate research supporting vaccines and monoclonal antibodies across targeted virus families, while keeping data, tools, and approaches aligned across participating groups.
What kind of award mechanism is this opportunity using?
This is an NIH cooperative agreement, which means NIH (specifically NIAID) is expected to have substantial programmatic involvement rather than acting solely as a passive funder.
What do UG3/UH3 and "Clinical Trial Not Allowed" mean for this FOA?
The FOA is explicitly listed as UG3/UH3 and "Clinical Trial Not Allowed." This indicates a phased cooperative structure that supports planning and early activities followed by implementation, but it does not support running clinical trials under this particular award.
What is a major deliverable the CDSC must provide?
A major deliverable is a collaborative platform for data sharing. This platform is intended to help the network harmonize and standardize key inputs across the ReVAMPP Centers.
What types of inputs does the FOA specifically mention harmonizing across the network?
The FOA highlights harmonizing and standardizing inputs such as reagents, assays, and animal models so network research can be compared and integrated more easily.
How does the CDSC support vaccine and monoclonal antibody research coordination?
The CDSC supports coordination by enabling consistent data and resource sharing and by making it easier for Centers to exchange knowledge related to structure/function-based vaccine solutions and antigen or immunogen design. It also helps the network assess and compare vaccine technology platforms across the targeted virus families studied by the Centers.
Does the CDSC have responsibilities related to vaccine platform assessment?
Yes. The CDSC is expected to help the network assess and compare the utility of different vaccine technology platforms for the virus families being studied by the ReVAMPP Centers, so decisions and research directions can be guided by shared evidence across sites.
What communications and project management duties are described for the CDSC?
The CDSC must facilitate effective communication across all ReVAMPP Centers by scheduling and managing meetings, building routines for regular coordination, and ensuring information is captured and distributed efficiently. It is also expected to track overall network progress and outputs, implying shared milestones, reporting structures, and mechanisms to monitor deliverables across sites.
Is the CDSC expected to create collaboration structures like working groups?
Yes. The CDSC should actively create opportunities for collaboration, including forming working groups around shared scientific or operational challenges, and providing administrative and informatics support so those groups can produce usable, network-wide outputs.
Is the CDSC only focused on internal network coordination?
No. Under the direction of NIAID, the CDSC is expected to collate information and facilitate exchange with other NIAID/NIH programs, U.S. Government partners, and other key stakeholders, helping connect the ReVAMPP Network to the broader pandemic preparedness ecosystem.
Which external stakeholders are specifically named in the opportunity description?
The opportunity specifically names the World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF), and the Coalition for Epidemic Preparedness Innovations (CEPI), among others as appropriate.
What is the role of NIAID in relation to the CDSC?
NIAID is the NIH institute directing this cooperative agreement and is expected to have substantial involvement. The CDSC is also expected to facilitate external exchange activities under NIAID direction.
What is the activity category and CFDA number listed for this opportunity?
The activity category is Health, and the CFDA number listed is 93.855.
What is the maximum award amount (award ceiling) shown for this opportunity?
The award ceiling shown is $1,500,000.
How many awards are anticipated?
The anticipated awards field is not specified in the provided information.
What were the key dates for this funding opportunity?
The opportunity was created on March 16, 2023, and the original closing date was June 8, 2023.
Who is eligible to apply?
Eligibility is broad and includes many typical U.S. applicant categories, such as state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.
Are there specific institution types called out as eligible?
Yes. The FOA explicitly calls out additional eligible applicant types including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, U.S. territories or possessions, and eligible federal agencies.
Are non-U.S. organizations eligible to apply?
No. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply based on the provided description.
Are foreign components allowed in any way?
Yes. Foreign components are allowed as defined by the NIH Grants Policy Statement, meaning a U.S. applicant may be able to include certain foreign collaborations or performance sites if justified and compliant, but the applicant organization itself must be domestic.
What is the main purpose of the CDSC in simple terms?
The CDSC is meant to fund the shared infrastructure and coordination function for a multi-center pandemic preparedness network. It builds the systems for data and resource sharing, aligns methods and models, organizes working relationships, tracks network productivity, and serves as an NIAID-directed connector to other major public and global health stakeholders.
Does this FOA fund the scientific research done by the ReVAMPP Centers directly?
This FOA is described as funding the coordination and data sharing hub (the CDSC). The scientific advances are expected to come from the ReVAMPP Centers, while the CDSC helps those advances move faster and remain comparable and reusable by keeping the network synchronized on platforms, standards, and communication.
Browse more opportunities from the same category: Health
Next opportunity: Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
Previous opportunity: IIJA Bureau of Land Management California Fuels Management and Community Fire Assistance Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 23 021
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 23 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 020 Funding Number: RFA AI 23 020 Agency: National Institutes of Health Category: Health Funding Amount: $10,000,000 |
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 019 Funding Number: RFA AI 23 019 Agency: National Institutes of Health Category: Health Funding Amount: $10,000,000 |
| NIH Administrative Supplements to Recover Losses due to Hurricanes Fiona and Ian Under the Consolidated Appropriations Act, 2023 (Admin Supp Clinical Trial Optional) Apply for PA 23 134 Funding Number: PA 23 134 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 140 Funding Number: RFA MH 23 140 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) Apply for PAR 23 138 Funding Number: PAR 23 138 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed) Apply for PAR 23 113 Funding Number: PAR 23 113 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Chemical Analysis Sites (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 009 Funding Number: RFA RM 23 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Limited Competition: Molecular Transducers of Physical Activity Bioinformatics Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 008 Funding Number: RFA RM 23 008 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Limited Competition: Molecular Transducers of Physical Activity Consortium Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 011 Funding Number: RFA RM 23 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Clinical Centers (U01 Clinical Trial Required) Apply for RFA RM 23 010 Funding Number: RFA RM 23 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 018 Funding Number: RFA AI 23 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integration and Coordination Center for the Common Fund Data Ecosystem (U54 Clinical Trial Not Allowed) Apply for RFA RM 23 002 Funding Number: RFA RM 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) Apply for RFA RM 23 006 Funding Number: RFA RM 23 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 260 Funding Number: RFA MH 23 260 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) Apply for RFA RM 23 007 Funding Number: RFA RM 23 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional) Apply for RFA NS 23 021 Funding Number: RFA NS 23 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) Apply for RFA RM 23 005 Funding Number: RFA RM 23 005 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed) Apply for PAR 23 132 Funding Number: PAR 23 132 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 022 Funding Number: RFA AI 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed) Apply for PAR 23 133 Funding Number: PAR 23 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 23 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.